ibcasertib   Click here for help

GtoPdb Ligand ID: 10475

Synonyms: chiauranib (pseudo INN) | CS-2164 | CS2164 | example 32 [US20100298358A1]
Compound class: Synthetic organic
Comment: CS2164 is a multi-target kinase inhibitor that exerts anti-angiogenic, anti-mitotic and anti-inflammatory effects that mediate anti-tumour activity [3]. Via inhibition of Aurora B CS2164 mediates inhibition of histone 3 (H3) phosphorylation which is associated with cell cycle arrest. CS2164 was developed by Chipscreen Biosciences and is claimed in their patent US20100298358A1 [2]. CS2164's chemical structure is an axact match for the INN 'ibcasertib' which was released in the WHO's proposed INN list 127 on 21 July 2022.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 86.47
Molecular weight 435.16
XLogP 4.94
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ccc2c(c1)nccc2Oc1ccc2c(c1)cccc2C(=O)Nc1ccccc1N
Isomeric SMILES COc1ccc2c(c1)nccc2Oc1ccc2c(c1)cccc2C(=O)Nc1ccccc1N
InChI InChI=1S/C27H21N3O3/c1-32-18-9-12-22-25(16-18)29-14-13-26(22)33-19-10-11-20-17(15-19)5-4-6-21(20)27(31)30-24-8-3-2-7-23(24)28/h2-16H,28H2,1H3,(H,30,31)
InChI Key BRKWREZNORONDU-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
CS2164 has advanced to Phase 1/2 clinical evaluation in solid tumours and lymphoma. Click here to link to ClinicalTrials.gov's full list of CS2164 (chiauranib) studies.